Bisphosphonates for the treatment of fibrous dysplasia of bone

Fibrous dysplasia of bone (FD) is a rare congenital disease, due to somatic mutation GNAS. This results in defect osteoblast differentiation and mineralization also an increase resorption by large active osteoclasts. Bone pain present half patients the main determinant quality life with FD. Bisphosphonates are known reduce risk fracture metastases or Paget's disease. may have similar effects In this article, we reviewed therapeutic potential bisphosphonates FD, improve strength occurrence fracture. We 234 articles examining effect on FD/McCune Albright Syndrome no date limit, PubMed selected highest methodology. Pamidronate therapy significantly decreased (urinary NTX, urinary serum CTX). radiological lesions FD (filling osteolytic lesion and/or cortical thickening). data intravenous pamidronate, however, has been obtained from observational studies randomized controlled trial available. Randomized placebo-controlled trials oral (alendronate risedronate) failed demonstrate significant decrease over placebo. Several including one shown mineral density (BMD) at sites bisphosphonate treatment. No reported. conclusion, be proposed treat persistent, moderate severe e.g., according guidelines FD/MAS International Consortium. Oral should not used indication.